Overview

Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue. The investigators' hypothesis states that CMV infection promotes tumor development and disease progression and inhibits immune responses against the tumor.

Phase:

N/A

Details

Lead Sponsor:

Karolinska Institutet
Karolinska University Hospital

Collaborator:

Karolinska University Hospital

Treatments:

Ganciclovir
Valganciclovir